Innovative Stroke Therapy Mobia Medical's flagship Vivistim Paired VNS System offers a first-of-its-kind FDA-approved solution for improving motor recovery in stroke survivors, presenting a compelling opportunity to target rehabilitation centers, hospitals, and clinics specializing in neurorehabilitation and stroke care.

Market Validation and Visibility Participation in major industry events like ISC 2025 showcases Mobia Medical's active engagement in the stroke and neurostimulation community, facilitating networking with key healthcare providers and decision-makers likely to adopt advanced rehabilitation technologies.

Growing Financial Footprint With revenues estimated between $25 million and $50 million and current funding of $65 million, Mobia Medical is well-positioned for expansion, enabling sales teams to explore new hospital contracts, distribution channels, and international markets for their innovative device.

Specialized Technology Focus The company's focus on neuroplasticity through vagus nerve stimulation aligns with emerging trends in personalized neurorehabilitation, opening avenues for collaboration with hospitals investing in cutting-edge, evidence-based stroke recovery solutions.

Competitive Positioning Compared to other medical device firms targeting neurological conditions, Mobia Medical’s niche focus on chronic stroke impairment recovery offers a differentiated value proposition, allowing sales efforts to emphasize the device's proven efficacy and FDA approval to healthcare providers seeking effective rehabilitation tools.